Paper. Basargin AG, Domokos A, Hennessey JJ et al.. Proceedings of the National Academy of Sciences of the United States of America, 8 Sep 2026.
Tags: LSD.
A PNAS team took LSD's four-ring core apart into nine simpler molecules, mapped which parts drive the hallucinogenic effect, and found two candidates with lower hallucinogenic and heart risk. A Nature Communications group used cryo-EM structures to design compounds that activate 5-HT2A while blocking 5-HT2B, the receptor linked to heart valve damage.
How much weight it carries: Lab and mouse work. These molecules are years away from human testing. (Lab + mice, Drug design, Peer reviewed)
A PNAS study strips LSD down to its minimal pharmacophore and finds safer, less hallucinogenic analogues.
Nine simplified ergolines were profiled across 5-HT2A/2B/2C; UCD0076 prefers 5-HT2C, shows antipsychotic-like effects in mice and avoids LSD's cardiotoxic liability. A separate report has a non-hallucinogenic LSD analogue boosting anti-tumour immunity in colorectal cancer models.